The purpose of this study was to identify and characterize the association of various clinical
variables and CYP3A5 genotypes with the pharmacokinetics of tacrolimus and outcome …

Pharmacogenetics has the potential to complement therapeutic drug monitoring in achieving
target blood concentrations of the immunosuppressive drugs during the critical early period …

To prevent acute rejection episodes, it is important to reach adequate tacrolimus (TRL)
exposure early after kidney transplantation. With a better understanding of the high …

Aim: The present study investigated in Tunisian renal transplant patients, genetic
polymorphisms of CYP3A4-392A> G and CYP3A5 6986A> G and their influence on …

We retrospectively examined the association of polymorphisms in the CYP3A, CYP2J2,
CYP2C8, and ABCB1 genes with pharmacokinetic (PKs) and pharmacodynamic (PDs) …

Retrospective studies have demonstrated that patients who are expressors of cytochrome
P4503A5 (CYP3A5) require a higher tacrolimus dose to achieve a therapeutic trough …

Background CYP3A5 genetic polymorphisms contribute to marked interindividual
differences in the metabolism of and response to tacrolimus in humans. Objective This study …

Tacrolimus is an immunosuppressive drug widely used in kidney transplantation.
Cytochrome P450 3A5 (CYP3A5) protein is involved in tacrolimus metabolism. Single …

Background: The aim of our study was to determine the impact of CYP3A5* 1 and CYP3A5*
3 on the kinetics of tacrolimus in renal transplant recipients. Material and methods: Forty …

The impact of CYP3A5* 3, a CYP3A5 nonexpresser genotype, on inhibitory effects of
diltiazem on tacrolimus metabolism has not been assessed. In retrospective study, when …